BeOne Medicines (BEIGF) Equity Income (2020 - 2023)

BeOne Medicines (BEIGF) has 4 years of Equity Income data on file, last reported at -$3.9 million in Q4 2023.

• Equity Income for Q4 2023 came in at -$3.9 million, up 29.29% year-over-year; the trailing twelve-month figure through Dec 2023 was -$6.3 million (up 79.88% YoY), and the FY2023 annual result was -$16.2 million, up 26.25% from the prior year.
• Equity Income fell to -$3.9 million in Q4 2023 per BEIGF's latest filing, from -$2.7 million in the prior quarter.
• Over five years, Equity Income peaked at $23.8 million in Q3 2021 and troughed at -$17.0 million in Q1 2022.
• A 4-year average of -$1.0 million and a median of -$2.5 million in 2021 frame the typical range for Equity Income.
• On a YoY basis, Equity Income climbed as much as 16718.18% in 2021 and fell as far as 614.79% in 2021.
• A 4-year view of Equity Income shows it stood at $1.9 million in 2020, then sank by 614.79% to -$9.5 million in 2021, then soared by 41.44% to -$5.6 million in 2022, then gained by 29.29% to -$3.9 million in 2023.
• Business Quant data shows BEIGF's Equity Income at -$3.9 million in Q4 2023, -$2.7 million in Q3 2023, and $470000.0 in Q2 2023.